Short answer
Innoviva, Inc. (INVA) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $108M (up 20.4% year over year) with net income of $90M.
Q3 2025 key financials · XBRL
- Revenue
- $108M
- +20.4% YoY · +7.5% QoQ
- Net income
- $90M
- +7312.0% YoY · +41.2% QoQ
- Operating margin
- 32.1%
- Gross margin
- 70.1%
- EPS (diluted)
- $1.11
- +5450.0% YoY · +13.3% QoQ
Source: XBRL data from the Innoviva, Inc. (INVA) Q3 2025 10-Q on SEC EDGAR. USD.
Innoviva, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New operational risk: FDA Priority Review of zoliflodacin with PDUFA date Dec 15, 2025, no advisory committee meeting planned (triggered by NDA acceptance in June 2025)
- Most materially updated financial risk: Convertible noteholders converted $192.5M principal to 11.1M shares in Aug 2025, reducing debt and interest expense
- Most impactful regulatory risk: La Jolla Royalty Agreement caps royalty payments to HCR at $225M through Jan 2031 or sales thresholds, impacting future royalties
- Competitive/market risk: Increased net product sales by 70% Q3 2025 vs Q3 2024 driven by commercial launch of XACDURO® and strategic commercialization efforts
- Financial liquidity risk: $476.5M cash and equivalents as of Sept 30, 2025, sufficient for 12+ months of operations including share repurchase program up to $125M authorized
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Innoviva, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.